Filter posts

Biotech IPO Boom or Bubble? The Opening Plenary at the BIO Investor Forum

With 31 (and counting) life sciences companies having already placed IPOs on the market within …

Chinese In-Licensing Continues to Strengthen

Chinese companies are eager to collaborate with their ex-China counterparts, and in-licensing agreements are outpacing …

China’s Biotech Innovators

As the Chinese government implements policies aimed at increasing innovation in the life sciences industry, …

The Return of the Biotech IPO

It isn’t just the volume of IPOs this summer that makes this window a victory …

Forecasted Sales Growth of Top Therapeutic Areas: Anti-Coagulants to Outpace

Although oncology has the largest market share in the therapeutics business, anti-coagulant products are expected …

R&D – Slow Growth Continues

According to a new report from EvaluatePharma, global pharmaceutical R&D had negative growth in 2012 …

Industry Growth Factor: Biologics

Last week, EvaluatePharma released their updated sales and R&D outlook for the drug industry in their …

Only 12% of Public Biotechs are Profitable

Of the 286 biotech companies trading on public exchanges today, 241 focus on drug development, …

Breakthrough Designations Reach 13

One of the outcomes of the 2012 Food and Drug Administration Safety and Innovation Act …

Results from the BIO Convention 2013 Meeting Analysis of Therapeutic In/Out Licensors

BIO’s results from the BIO 2013 Convention 1×1 meeting analysis conducted to identify trends and intentions …